RU96119350A - METHOD FOR REPRODUCING IN VITRO PROTEOLYTIC ACTIVITY NS3 PROTEASES OF HEPATITIS C VIRUS (NSU) - Google Patents

METHOD FOR REPRODUCING IN VITRO PROTEOLYTIC ACTIVITY NS3 PROTEASES OF HEPATITIS C VIRUS (NSU)

Info

Publication number
RU96119350A
RU96119350A RU96119350/13A RU96119350A RU96119350A RU 96119350 A RU96119350 A RU 96119350A RU 96119350/13 A RU96119350/13 A RU 96119350/13A RU 96119350 A RU96119350 A RU 96119350A RU 96119350 A RU96119350 A RU 96119350A
Authority
RU
Russia
Prior art keywords
ns4a
proteolytic activity
reproducing
sequences
hcy
Prior art date
Application number
RU96119350/13A
Other languages
Russian (ru)
Other versions
RU2149185C1 (en
Inventor
де Франческо Раффаэле
Фаилла Кристина
Томеи Личия
Original Assignee
Иституто Ди Ричерке Ди Биологиа Молеколаре П.Анджелетти С.п.А.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from ITRM940092A external-priority patent/IT1272179B/en
Application filed by Иституто Ди Ричерке Ди Биологиа Молеколаре П.Анджелетти С.п.А. filed Critical Иституто Ди Ричерке Ди Биологиа Молеколаре П.Анджелетти С.п.А.
Publication of RU96119350A publication Critical patent/RU96119350A/en
Application granted granted Critical
Publication of RU2149185C1 publication Critical patent/RU2149185C1/en

Links

Claims (7)

1. Способ репродукции in vitro протеолитической активности HCY NS3 протеазы, отличающийся тем, что как последовательности, содержащиеся в NS3, так и последовательности, содержащиеся в NS4A, используются в реакционной смеси.1. A method for reproducing the in vitro proteolytic activity of HCY NS3 protease, characterized in that both the sequences contained in NS3 and the sequences contained in NS4A are used in the reaction mixture. 2. Способ репродукции in vitro протеолитической активности HCY NS3 протеазы по п. 1, в котором NS4A присутствует в соотношении 1:1 относительно NS3. 2. An in vitro method for reproducing the proteolytic activity of HCY NS3 protease according to claim 1, wherein NS4A is present in a 1: 1 ratio relative to NS3. 3. Способ репродукции in vitro протеолитической активности HCY NS3 протеазы по п. 1 или 2, в котором NS3 и NS4A вводятся в реакционную смесь в виде NS3- NS4A предшественника, причем указанный предшественник, в случае аутопротеолитической ситуации, образует эквимолярные количества NS3 и NS4A. 3. An in vitro method for reproducing the proteolytic activity of HCY NS3 protease according to claim 1 or 2, wherein NS3 and NS4A are introduced into the reaction mixture as an NS3-NS4A precursor, said precursor, in the case of an autoproteolytic situation, forms equimolar amounts of NS3 and NS4A. 4. Способ репродукции in vitro протеолитической активности HCY NS3 протеазы по любому из предшествующих пунктов, отличающийся тем, что сайт расщепления между NS3 и NS4A мутируется в предшественнике так, что NS4A остается ковалентно связанным с NS3, и при этом далее возникает возможность удаления из указанного не расщепляемого предшественника последовательностей, которые не оказывают влияния на протеолитическую активность NS3. 4. The method of reproducing in vitro the proteolytic activity of HCY NS3 protease according to any one of the preceding paragraphs, characterized in that the cleavage site between NS3 and NS4A is mutated in the precursor so that the NS4A remains covalently linked to NS3, and further there is the possibility of removal from the specified cleavable precursor sequences that do not affect the proteolytic activity of NS3. 5. Композиция вещества, отличающаяся тем, что она содержит последовательности NS3 и NS4A согласно пп. 1 - 4. 5. The composition of the substance, characterized in that it contains the sequence of NS3 and NS4A according to paragraphs. fourteen. 6. Композиция вещества по п. 5, включающая белки, последовательности которых представлены последовательностями SEQ ID N 1 и SEQ ID N 2 или последовательностями, содержащимися в них, либо являющимися их производными. 6. The composition of a substance according to claim 5, comprising proteins, the sequences of which are represented by the sequences SEQ ID N 1 and SEQ ID N 2 or the sequences contained in them or their derivatives. 7. Применение композиций вещества по пп. 5 и 6 для реализации энзиматического теста, обеспечивающего возможность селекции в терапевтических целях, соединений, ингибирующих энзиматическую активность, связанную с NS3. 7. The use of compositions of the substance according to paragraphs. 5 and 6 for the implementation of an enzymatic test, allowing the selection for therapeutic purposes, compounds that inhibit the enzymatic activity associated with NS3.
RU96119350A 1994-02-23 1995-02-14 Method of in vitro reproduction of proteolytic activity of hepatitis c virus protease ns3 RU2149185C1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
ITRM940092A IT1272179B (en) 1994-02-23 1994-02-23 METHODOLOGY TO REPRODUCE IN VITRO THE PROTEOLITHIC ACTIVITY OF THE NS3 PROTEASE OF THE VIRUS HCV.
ITRM94A000092 1994-02-23
PCT/IT1995/000018 WO1995022985A1 (en) 1994-02-23 1995-02-14 Method for reproducing in vitro the proteolytic activity of the ns3 protease of hepatitis c virus (hcv)

Publications (2)

Publication Number Publication Date
RU96119350A true RU96119350A (en) 1999-02-10
RU2149185C1 RU2149185C1 (en) 2000-05-20

Family

ID=11402272

Family Applications (1)

Application Number Title Priority Date Filing Date
RU96119350A RU2149185C1 (en) 1994-02-23 1995-02-14 Method of in vitro reproduction of proteolytic activity of hepatitis c virus protease ns3

Country Status (15)

Country Link
US (1) US5739002A (en)
EP (1) EP0746333B1 (en)
JP (1) JP3280384B2 (en)
AT (1) ATE179611T1 (en)
AU (1) AU691259B2 (en)
BR (1) BR9506931A (en)
CA (1) CA2182521C (en)
DE (1) DE69509504T2 (en)
DK (1) DK0746333T3 (en)
ES (1) ES2132644T3 (en)
GR (1) GR3030166T3 (en)
HK (1) HK1010988A1 (en)
IT (1) IT1272179B (en)
RU (1) RU2149185C1 (en)
WO (1) WO1995022985A1 (en)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5767233A (en) * 1995-05-12 1998-06-16 Schering Corporation Soluble cleavable substrates of the hepatitis C virus protease
US5843752A (en) * 1995-05-12 1998-12-01 Schering Corporation Soluble active hepatitis C virus protease
IT1278077B1 (en) 1995-05-25 1997-11-17 Angeletti P Ist Richerche Bio METHODOLOGY TO REPRODUCE IN VITRO THE ACTIVITIES OF RNA-DEPENDENT RNA POLYMERASE AND OF TERMINAL NUCLEOTIDYLTRANSPHERASE CODED BY THE
US5990276A (en) * 1996-05-10 1999-11-23 Schering Corporation Synthetic inhibitors of hepatitis C virus NS3 protease
EP0907659A1 (en) * 1996-05-10 1999-04-14 Schering Corporation Synthetic inhibitors of hepatitis c virus ns3 protease
US6153579A (en) 1996-09-12 2000-11-28 Vertex Pharmaceuticals, Incorporated Crystallizable compositions comprising a hepatitis C virus NS3 protease domain/NS4A complex
EP1364961B1 (en) * 1996-09-12 2006-11-22 Vertex Pharmaceuticals Incorporated Crystallizable compositions comprising a hepatitis c virus ns3 protease domain/ns4a complex and crystals thereby obtained
US5861297A (en) * 1996-09-27 1999-01-19 Merck & Co., Inc. Detergent-free hepatitis C protease
AU4904397A (en) 1996-10-17 1998-05-11 Chiron Corporation Protease regulator screening assay
WO1998037180A2 (en) * 1997-02-22 1998-08-27 Abbott Laboratories Hcv fusion protease and polynucleotide encoding same
US6251583B1 (en) 1998-04-27 2001-06-26 Schering Corporation Peptide substrates for HCV NS3 protease assays
US6280940B1 (en) 1998-08-05 2001-08-28 Agouron Pharmaceuticals, Inc. Reporter gene system for use in cell-based assessment of inhibitors of the Hepatitis C virus protease
US6323180B1 (en) 1998-08-10 2001-11-27 Boehringer Ingelheim (Canada) Ltd Hepatitis C inhibitor tri-peptides
JP2002534084A (en) * 1999-01-08 2002-10-15 ブリストル−マイヤーズ スクイブ カンパニー Modified form of hepatitis C virus NS3 protease
WO2001002601A2 (en) * 1999-07-07 2001-01-11 Du Pont Pharmaceuticals Company Cell-based assay systems for examining hcv ns3 protease activity
WO2001038538A1 (en) * 1999-11-23 2001-05-31 Viropharma Incorporated Polymerase compositions and methods of use thereof
MY164523A (en) 2000-05-23 2017-12-29 Univ Degli Studi Cagliari Methods and compositions for treating hepatitis c virus
HU229997B1 (en) * 2000-07-21 2015-04-28 Dendreon Corp San Diego Peptides as ns3-serine protease inhibitors of hepatitis c virus
MXPA03000626A (en) * 2000-07-21 2004-07-30 Schering Corp Novel peptides as ns3-serine protease inhibitors of hepatitis c virus.
AR029851A1 (en) * 2000-07-21 2003-07-16 Dendreon Corp NEW PEPTIDES AS INHIBITORS OF NS3-SERINA PROTEASA DEL VIRUS DE HEPATITIS C
US7244721B2 (en) * 2000-07-21 2007-07-17 Schering Corporation Peptides as NS3-serine protease inhibitors of hepatitis C virus
US7022830B2 (en) 2000-08-17 2006-04-04 Tripep Ab Hepatitis C virus codon optimized non-structural NS3/4A fusion gene
US8198426B2 (en) * 2001-01-23 2012-06-12 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. Hepatitis c virus replicons and replicon enhanced cells
JP2005504087A (en) * 2001-09-28 2005-02-10 イデニクス（ケイマン）リミテツド Methods and compositions for the treatment of hepatitis C virus using 4 'modified nucleosides
CA2461380C (en) 2001-10-11 2011-03-22 Merck & Co., Inc. Hepatitis c virus vaccine
ES2344253T3 (en) 2001-10-11 2010-08-23 MERCK SHARP & DOHME CORP. VACCINE AGAINST THE VIRUS OF HEPATITIS C.
CA2481171A1 (en) 2002-04-16 2003-10-30 Merck & Co., Inc. Hepatitis c virus assay systems
DE602004024658D1 (en) 2003-02-13 2010-01-28 Merck & Co Inc METHOD FOR TRANSFERRING CELL CULTURAL REPLICATION ACTIVITY TO DIFFERENT HEPATITIS C VIRUS ISOLATES
WO2006121468A1 (en) * 2004-11-22 2006-11-16 Genelabs Technologies, Inc. 5-nitro-nucleoside compounds for treating viral infections
KR20070106781A (en) * 2005-02-28 2007-11-05 제네랩스 테크놀로지스, 인코포레이티드 Tricyclic-nucleoside prodrugs for treating viral infections
WO2006102087A2 (en) * 2005-03-22 2006-09-28 Merck & Co., Inc. Hcv protease substrates
AR056327A1 (en) * 2005-04-25 2007-10-03 Genelabs Tech Inc NUCLEOSID COMPOUNDS FOR THE TREATMENT OF VIRAL INFECTIONS
US20060293320A1 (en) * 2005-06-24 2006-12-28 Genelabs Technologies, Inc. Heteroaryl derivatives for treating viruses
DK1945797T3 (en) * 2005-10-28 2012-08-06 Boehringer Ingelheim Int Hepatitis C virus NS2 / 3 activity assay
WO2007145894A2 (en) 2006-06-08 2007-12-21 Merck & Co., Inc. A rapid method to determine inhibitor sensitivity of ns3/4a protease sequences
KR20090029827A (en) * 2006-07-20 2009-03-23 제네랩스 테크놀로지스, 인코포레이티드 Polycyclic viral inhibitors
US20100216161A1 (en) 2009-02-26 2010-08-26 Vertex Pharmaceuticals Incorporated Method for identifying protease inhibitors
US20100143886A1 (en) 2007-03-09 2010-06-10 Ludmerer Steven W In vivo hcv resistance to anti-viral inhibitors
WO2009022236A2 (en) 2007-08-16 2009-02-19 Tripep Ab Immunogen platform
WO2009029729A1 (en) * 2007-08-31 2009-03-05 Genelabs Technologies, Inc. Amino tricyclic-nucleoside compounds, compositions, and methods of use
US8324239B2 (en) 2010-04-21 2012-12-04 Novartis Ag Furopyridine compounds and uses thereof
EA201300160A1 (en) 2010-07-22 2013-06-28 Новартис Аг 2,3,5-Trisulfonated TIOPHENES AND THEIR APPLICATION
US9351989B2 (en) 2010-12-29 2016-05-31 Inhibitex, Inc. Substituted purine nucleosides, phosphoroamidate and phosphorodiamidate derivatives for treatment of viral infections
WO2014139587A1 (en) 2013-03-15 2014-09-18 Okairòs Ag Improved poxviral vaccines
WO2017025782A1 (en) 2014-09-17 2017-02-16 Glaxosmithkline Biologicals Sa Improved poxviral vaccines
US11965191B2 (en) 2018-01-18 2024-04-23 California Institute Of Technology Programmable protein circuits in living cells
WO2019147478A2 (en) 2018-01-18 2019-08-01 California Institute Of Technology Programmable protein circuits in living cells
US11453893B2 (en) 2018-08-30 2022-09-27 California Institute Of Technology RNA-based delivery systems with levels of control
WO2020047320A1 (en) 2018-08-31 2020-03-05 California Institute Of Technology Synthetic protein circuits detecting signal transducer activity
US11667676B2 (en) 2019-01-10 2023-06-06 California Institute Of Technology Synthetic system for tunable thresholding of protein signals

Similar Documents

Publication Publication Date Title
RU96119350A (en) METHOD FOR REPRODUCING IN VITRO PROTEOLYTIC ACTIVITY NS3 PROTEASES OF HEPATITIS C VIRUS (NSU)
CA2182521A1 (en) Method for Reproducing in Vitro the Proteolytic Activity of the NS3 Protease of Hepatitis C Virus (HCV)
Henderson et al. Primary structure of human carbonic anhydrase C.
JP2701932B2 (en) Protease inhibitor
FI946066A0 (en) New sequences of the hepatitis C virus genotypes and their use as therapeutic and diagnostic agents
Dembitsky et al. Synthesis and biological activity of α-aminoboronic acids, amine-carboxyboranes and their derivatives
WO2003087092A3 (en) Inhibitors of serine proteases, particularly hepatitis c virus ns3 - ns4 protease
Holladay et al. Synthetic and enzyme inhibition studies of pepstatin analogs containing hydroxyethylene and ketomethylene dipeptide isosteres
EP0815123B1 (en) Beta-sheet mimetics and use thereof as protease inhibitors
NZ319786A (en) HCV NS3 protein fragments with helicase activity and improved solubility
Hörlein et al. Amino Acid Sequence of the Aminoterminal Segment of Dermatosparactic Calf‐Skin Procollagen Type I
WO1990003390A1 (en) Peptidyl inhibitors of the initiation of coagulation
EP0802986A1 (en) Methods of determining endogenous thrombin potential (etp) and thrombin substrates for use in said methods
Gopi et al. Proteolytic stability of β-peptide bonds probed using quenched fluorescent substrates incorporating a hemoglobin cleavage site
McConnell et al. New leupeptin analogs: Synthesis and inhibition data
Briet et al. Cleavage and activation of human prothrombin by Echiscarinatus venom
De Francesco et al. Mechanisms of hepatitis C virus NS3 proteinase inhibitors
Chaiken et al. A solid phase synthetic study of structure-function relationships in the amino-terminal region of staphylococcal nuclease
US5776903A (en) Peptide derivatives usable as zinc endopeptidase 24-15 inhibitors
Okada et al. Synthesis of plasmin substrates and relationship between their structure and plasmin activity
Zhu et al. Discovery of transition state factor Xa inhibitors as potential anticoagulant agents
Wieczorek et al. Covalent hybrids of ovomucoid third domains made from one synthetic and one natural peptide chain
Ferguson et al. Formation and stability of the complex formed between human antithrombin-III and thrombin
Husbyn et al. Linear analogues derived from the first EGF‐like domain of human blood coagulation factor VII: enhanced inhibition of FVIIa/TF complex activity by backbone modification through aspartimide formation
FR2710917A1 (en) New therapeutically active peptide derivatives in the blood coagulation cascade, process for their preparation and pharmaceutical compositions containing them